Unity Bio (UBX) Stock Forecast, Price Target & Predictions
UBX Stock Forecast
Unity Bio stock forecast is as follows: a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
UBX Analyst Ratings
According to 4 Wall Street analysts, Unity Bio's rating consensus is 'Buy'. The analyst rating breakdown for UBX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 22, 2024 | Rodman & Renshaw | Buy | Initialise | |
| Apr 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 16, 2023 | Wedbush | Outperform | Upgrade | |
| Aug 15, 2022 | Citigroup | Buy | Buy | Hold |
Unity Bio's last stock rating was published by Rodman & Renshaw on Aug 22, 2024. The company Initialise its UBX rating from "null" to "Buy".
Unity Bio Financial Forecast
Unity Bio Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
Unity Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. UBX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Unity Bio EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict UBX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Unity Bio's previous annual EBITDA (undefined) of $NaN.
Unity Bio Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-7.93M | $-6.80M | $-7.77M |
| High Forecast | $-7.93M | $-6.80M | $-7.77M |
| Low Forecast | $-7.93M | $-6.80M | $-7.77M |
| Surprise % | - | - | - |
Unity Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. UBX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Unity Bio SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Unity Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to UBX last annual SG&A of $NaN (undefined).
Unity Bio EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-0.47 | $-0.40 | $-0.46 |
| High Forecast | $-0.47 | $-0.40 | $-0.46 |
| Low Forecast | $-0.47 | $-0.40 | $-0.46 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Unity Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to UBX previous annual EPS of $NaN (undefined).
Unity Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| UBX | Unity Bio | - | - | 6796.55% | Buy |
| NTLA | Intellia Therapeutics | - | - | 739.86% | Buy |
| OVID | Ovid Therapeutics | - | - | 591.51% | Buy |
| HRTX | Heron Therapeutics | - | - | 560.38% | Buy |
| PRME | Prime Medicine | - | - | 480.81% | Buy |
| EDIT | Editas Medicine | - | - | 442.19% | Buy |
| DRMA | Dermata Therapeutics | - | - | 421.74% | Buy |
| VERV | Verve Therapeutics | - | - | 313.04% | Buy |
| ABOS | Acumen Pharmaceuticals | - | - | 203.03% | Buy |
| FIXX | Q32 Bio | - | - | 190.32% | Buy |
| NUVB | Nuvation Bio | - | - | 150.00% | Buy |
| BEAM | Beam Therapeutics | - | - | 148.09% | Buy |
| NXTC | NextCure | - | - | 132.56% | Buy |
| AVIR | Atea Pharmaceuticals | - | - | 111.69% | Hold |
| RXRX | Recursion Pharmaceuticals | - | - | 68.17% | Hold |
| CNTB | Connect Biopharma | - | - | 51.52% | Buy |
| HOOK | HOOKIPA Pharma | - | - | 30.43% | Buy |
| RNA | Avidity Biosciences | - | - | 28.05% | Buy |
| EXAI | Exscientia | - | - | 3.31% | Hold |